Confronting an influenza pandemic with inexpensive generic agents: can it be done?
- 1 September 2008
- journal article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 8 (9) , 571-576
- https://doi.org/10.1016/s1473-3099(08)70070-7
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Influenza Viruses: Basic Biology and Potential Drug TargetsInfectious Disorders - Drug Targets, 2007
- Peroxisome Proliferator-Activated Receptors and Acute Lung InjuryPPAR Research, 2007
- Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A virusesVirology Journal, 2007
- Statins and sepsis: multiple modifications at multiple levelsThe Lancet Infectious Diseases, 2007
- Resolution of in flammation: state of the art, definitions and termsThe FASEB Journal, 2007
- A question of self‐preservation: immunopathology in influenza virus infectionImmunology & Cell Biology, 2007
- Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?Fundamental & Clinical Pharmacology, 2006
- Vaccine Development for an Imminent Pandemic: Why We Should Worry, What We Must DoHuman Vaccines, 2006
- Activation of Mitogen-Activated Protein Kinases by Peroxisome Proliferator-Activated Receptor Ligands: An Example of Nongenomic SignalingMolecular Pharmacology, 2005
- Therapeutic Effect of Erythromycin on Influenza Virus-induced Lung Injury in MiceAmerican Journal of Respiratory and Critical Care Medicine, 1998